Literature DB >> 16685192

Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.

Daniel A Duprez1.   

Abstract

The concept of hypertension as primarily a consequence of altered hemodynamics has changed. Many factors are now implicated in the development of hypertensive vascular disease, and the renin-angiotensin-aldosterone system (RAAS) appears to be one of the most significant. Angiotensin II, the principal effector peptide of the RAAS, has far-reaching effects on vascular structure, growth and fibrosis, and is a key regulator of vascular remodeling and inflammation. Reactive oxygen species and a network of signaling pathways mediate angiotensin II and cellular mechanisms that promote remodeling and inflammation. The involvement of aldosterone in vessel-wall and myocardial remodeling has also come under intensive research scrutiny. Treatments that block the pathologic effects of the RAAS at several points have been shown to limit target-organ damage in hypertension and to decrease cardiovascular morbidity and mortality. Understanding the molecular and cellular mechanisms that participate in the early development of hypertensive vascular disease may lead to more targeted treatment and improved outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685192     DOI: 10.1097/01.hjh.0000226182.60321.69

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  54 in total

1.  Rigid and remodelled: cerebrovascular structure and function after experimental high-thoracic spinal cord transection.

Authors:  A A Phillips; N Matin; B Frias; M M Z Zheng; M Jia; C West; A M Dorrance; I Laher; A V Krassioukov
Journal:  J Physiol       Date:  2016-01-18       Impact factor: 5.182

Review 2.  Chronic Inflammatory Diseases and Endothelial Dysfunction.

Authors:  Xavier Castellon; Vera Bogdanova
Journal:  Aging Dis       Date:  2016-01-02       Impact factor: 6.745

3.  Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Ping Tepper; Emma Barinas-Mitchell; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Clin Exp Hypertens       Date:  2011-10-18       Impact factor: 1.749

4.  Role of RAAS Inhibition in the Prevention of Cardiovascular Disease.

Authors:  Henry A Tran; Arthur Schwartzbard; Howard S Weintraub
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-08

Review 5.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 6.  Coronary microvascular disease as an early culprit in the pathophysiology of diabetes and metabolic syndrome.

Authors:  Hicham Labazi; Aaron J Trask
Journal:  Pharmacol Res       Date:  2017-07-09       Impact factor: 7.658

7.  Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis.

Authors:  C Custodero; R T Mankowski; S A Lee; Z Chen; S Wu; T M Manini; J Hincapie Echeverri; C Sabbà; D P Beavers; J A Cauley; M A Espeland; R A Fielding; S B Kritchevsky; C K Liu; M M McDermott; M E Miller; R P Tracy; A B Newman; W T Ambrosius; M Pahor; S D Anton
Journal:  Ageing Res Rev       Date:  2018-05-25       Impact factor: 10.895

8.  Mechanism of Hormone Peptide Activation of a GPCR: Angiotensin II Activated State of AT1R Initiated by van der Waals Attraction.

Authors:  Khuraijam Dhanachandra Singh; Hamiyet Unal; Russell Desnoyer; Sadashiva S Karnik
Journal:  J Chem Inf Model       Date:  2019-01-16       Impact factor: 4.956

9.  Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?

Authors:  Daniel I Simon; Norman M Simon
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

Review 10.  Treatment of prehypertension in diabetes and metabolic syndrome: what are the pros?

Authors:  Julian Segura; Luis M Ruilope
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.